Chris Lee, the Asia-Pacific regional head for Bayer Schering Pharma, recently discussed with the China Bureau of PharmAsia News the German-headquartered outfit's plans to expand exchanges between scientists at its new R&D center in Beijing and other Bayer research outposts, and projections that China will be a global growth driver into the future (PharmAsia News, Feb.19, 2009).
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
